Trial results

Extension to Study 200952 to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus Subjects

NCT02750930 on ClinicalTrials.gov · last registry update 2019-07-12

Stopped early, having planned 8 participants. The sponsor logged completion for 21 March 2017. Primary outcome, as filed: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs). albiglutide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended. The registry entry has been edited 1 time since then.

Status

TERMINATED

Phase

P4

Drug

albiglutide

Tanzeum

Sponsor

GlaxoSmithKline

Sponsor type

Industry

Enrollment

8

Started

2016-10-07

Primary completion

2017-03-21 actual

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Primary outcome

Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

Conditions studied

Diabetes Mellitus, Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the albiglutide page for this molecule’s full trial and approval history.